Cargando…

PRObiotics and SYNbiotics to improve gut health and growth in infants in western Kenya (PROSYNK Trial): study protocol for a 4-arm, open-label, randomised, controlled trial

BACKGROUND: Malnutrition amongst under-fives remains common in resource-poor countries and is resistant to current interventions. New opportunities have emerged to target “environmental enteric dysfunction” (EED) that refers to the abnormal gut structure and function that results from colonisation o...

Descripción completa

Detalles Bibliográficos
Autores principales: Otiti, Mary Iwaret, Kariuki, Simon, Wang, Duolao, Hall, Lindsay J., Ter Kuile, Feiko O., Allen, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996226/
https://www.ncbi.nlm.nih.gov/pubmed/35410317
http://dx.doi.org/10.1186/s13063-022-06211-1
_version_ 1784684450744893440
author Otiti, Mary Iwaret
Kariuki, Simon
Wang, Duolao
Hall, Lindsay J.
Ter Kuile, Feiko O.
Allen, Stephen
author_facet Otiti, Mary Iwaret
Kariuki, Simon
Wang, Duolao
Hall, Lindsay J.
Ter Kuile, Feiko O.
Allen, Stephen
author_sort Otiti, Mary Iwaret
collection PubMed
description BACKGROUND: Malnutrition amongst under-fives remains common in resource-poor countries and is resistant to current interventions. New opportunities have emerged to target “environmental enteric dysfunction” (EED) that refers to the abnormal gut structure and function that results from colonisation of the gut with pathogenic microbes and compromises nutrition and growth in early life. Although the gut microbiome may provide a defence against ingested gut pathogens through colonisation resistance, its development is adversely affected by multiple environmental factors. Dietary supplements of pro- or synbiotics may build the resilience of the gut microbiome against these environmental factors and boost colonisation resistance. We aim to assess whether dietary supplementation of newborns in rural Kenya with pro/synbiotics prevents or ameliorates EED and improves growth. METHODS: Six hundred newborns less than 4 days old will be recruited from Homa Bay County Teaching and Referral Hospital, western Kenya. Newborns will be randomly allocated, stratified by HIV exposure, in a 1:1:1:1 ratio to one of 4 study arms to receive either of two synbiotics, a probiotic or no supplement. Supplements will be given daily for 10 days and then weekly until 6 months of age. Participants will be followed until the age of 2 years. The primary outcome is systemic inflammation at 6 months assessed by plasma alpha-1-acid glycoprotein. Secondary outcomes include biomarkers of gut health and growth, anthropometric indices, morbidity and mortality. DISCUSSION: As dietary supplements with pro- or synbiotics may improve gut health and can be administered in early life, our findings may inform the package of interventions to prevent malnutrition and improve growth in Africa and similar low-resource settings. TRIAL REGISTRATION: Pan African Clinical Trials Registry, Trial number: PACTR202003893276712. Date: 02/03/2020 https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=9798 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-022-06211-1.
format Online
Article
Text
id pubmed-8996226
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-89962262022-04-11 PRObiotics and SYNbiotics to improve gut health and growth in infants in western Kenya (PROSYNK Trial): study protocol for a 4-arm, open-label, randomised, controlled trial Otiti, Mary Iwaret Kariuki, Simon Wang, Duolao Hall, Lindsay J. Ter Kuile, Feiko O. Allen, Stephen Trials Study Protocol BACKGROUND: Malnutrition amongst under-fives remains common in resource-poor countries and is resistant to current interventions. New opportunities have emerged to target “environmental enteric dysfunction” (EED) that refers to the abnormal gut structure and function that results from colonisation of the gut with pathogenic microbes and compromises nutrition and growth in early life. Although the gut microbiome may provide a defence against ingested gut pathogens through colonisation resistance, its development is adversely affected by multiple environmental factors. Dietary supplements of pro- or synbiotics may build the resilience of the gut microbiome against these environmental factors and boost colonisation resistance. We aim to assess whether dietary supplementation of newborns in rural Kenya with pro/synbiotics prevents or ameliorates EED and improves growth. METHODS: Six hundred newborns less than 4 days old will be recruited from Homa Bay County Teaching and Referral Hospital, western Kenya. Newborns will be randomly allocated, stratified by HIV exposure, in a 1:1:1:1 ratio to one of 4 study arms to receive either of two synbiotics, a probiotic or no supplement. Supplements will be given daily for 10 days and then weekly until 6 months of age. Participants will be followed until the age of 2 years. The primary outcome is systemic inflammation at 6 months assessed by plasma alpha-1-acid glycoprotein. Secondary outcomes include biomarkers of gut health and growth, anthropometric indices, morbidity and mortality. DISCUSSION: As dietary supplements with pro- or synbiotics may improve gut health and can be administered in early life, our findings may inform the package of interventions to prevent malnutrition and improve growth in Africa and similar low-resource settings. TRIAL REGISTRATION: Pan African Clinical Trials Registry, Trial number: PACTR202003893276712. Date: 02/03/2020 https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=9798 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-022-06211-1. BioMed Central 2022-04-11 /pmc/articles/PMC8996226/ /pubmed/35410317 http://dx.doi.org/10.1186/s13063-022-06211-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Study Protocol
Otiti, Mary Iwaret
Kariuki, Simon
Wang, Duolao
Hall, Lindsay J.
Ter Kuile, Feiko O.
Allen, Stephen
PRObiotics and SYNbiotics to improve gut health and growth in infants in western Kenya (PROSYNK Trial): study protocol for a 4-arm, open-label, randomised, controlled trial
title PRObiotics and SYNbiotics to improve gut health and growth in infants in western Kenya (PROSYNK Trial): study protocol for a 4-arm, open-label, randomised, controlled trial
title_full PRObiotics and SYNbiotics to improve gut health and growth in infants in western Kenya (PROSYNK Trial): study protocol for a 4-arm, open-label, randomised, controlled trial
title_fullStr PRObiotics and SYNbiotics to improve gut health and growth in infants in western Kenya (PROSYNK Trial): study protocol for a 4-arm, open-label, randomised, controlled trial
title_full_unstemmed PRObiotics and SYNbiotics to improve gut health and growth in infants in western Kenya (PROSYNK Trial): study protocol for a 4-arm, open-label, randomised, controlled trial
title_short PRObiotics and SYNbiotics to improve gut health and growth in infants in western Kenya (PROSYNK Trial): study protocol for a 4-arm, open-label, randomised, controlled trial
title_sort probiotics and synbiotics to improve gut health and growth in infants in western kenya (prosynk trial): study protocol for a 4-arm, open-label, randomised, controlled trial
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996226/
https://www.ncbi.nlm.nih.gov/pubmed/35410317
http://dx.doi.org/10.1186/s13063-022-06211-1
work_keys_str_mv AT otitimaryiwaret probioticsandsynbioticstoimproveguthealthandgrowthininfantsinwesternkenyaprosynktrialstudyprotocolfora4armopenlabelrandomisedcontrolledtrial
AT kariukisimon probioticsandsynbioticstoimproveguthealthandgrowthininfantsinwesternkenyaprosynktrialstudyprotocolfora4armopenlabelrandomisedcontrolledtrial
AT wangduolao probioticsandsynbioticstoimproveguthealthandgrowthininfantsinwesternkenyaprosynktrialstudyprotocolfora4armopenlabelrandomisedcontrolledtrial
AT halllindsayj probioticsandsynbioticstoimproveguthealthandgrowthininfantsinwesternkenyaprosynktrialstudyprotocolfora4armopenlabelrandomisedcontrolledtrial
AT terkuilefeikoo probioticsandsynbioticstoimproveguthealthandgrowthininfantsinwesternkenyaprosynktrialstudyprotocolfora4armopenlabelrandomisedcontrolledtrial
AT allenstephen probioticsandsynbioticstoimproveguthealthandgrowthininfantsinwesternkenyaprosynktrialstudyprotocolfora4armopenlabelrandomisedcontrolledtrial